Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone.
The histologic and histochemical features of quinolone-induced arthropathy were studied using 14 skeletally immature Beagle dogs (3 to 4 months old) dosed orally with difloxacin at 300 mg/kg body weight once daily for 1, 2, 5, or 7 days. A placebo was given to eight other age-matched Beagle dogs that served as controls. A scoring technique that included lesion size and histologic features was used to determine the progression of lesions. Articular-epiphyseal cartilage complexes on the femoral and humeral heads and tibial tarsal bone were identified as predilection sites. Within predilection sites on femoral and humeral heads, lesions developed in specific areas. Lesions appeared within 2 days of the onset of treatment, and lesion scores increased with time. Grossly, the lesions were raised, fluid-filled vesicles on the articular surface. Histologic changes included vesicle formation with loss of proteoglycan, clumping of unmasked collagen, and degeneration and necrosis of chondrocytes. In lesions with higher scores, chondrocytes were often in clusters or they were undergoing metaplasia toward spindle-shaped cells. Although dissolution of matrix and necrosis of chondrocytes were typical of all lesions, smaller lesions had histologically normal chondrocytes adjacent to small vesicles. In sections stained with toluidine blue, proteoglycan was aggregated with collagen fibrils or was absent from the matrix adjacent to vesicles. Unique features, such as biomechanical forces, may predispose specific areas of articular cartilage to develop lesions.
Burkhardt
J E
JE
Purdue University School of Veterinary Medicine, West Lafayette, IN.
Hill
M A
MA
Carlton
W W
WW
Kesterson
J W
JW
D000367:Age Factors; D000818:Animals; D000890:Anti-Infective Agents; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D002358:Cartilage, Articular / Q000187:drug effects* / Q000473:pathology; D002807:Chondroitin / Q000378:metabolism; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000633:toxicity; D004285:Dogs; D005260:Female; D005270:Femur Head / Q000187:drug effects / Q000473:pathology; D024841:Fluoroquinolones; D006811:Humerus / Q000187:drug effects / Q000473:pathology; D008297:Male; D011509:Proteoglycans / Q000378:metabolism
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D011509:Proteoglycans; D002939:Ciprofloxacin; C047225:difloxacin; D002807:Chondroitin